Prothena (PRTA)
(Real Time Quote from BATS)
$19.88 USD
-0.16 (-0.80%)
Updated May 28, 2024 11:04 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 21 - 40 ( 331 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Lecanemab SC Data Might Help Guide PRX012 Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Key Takeaways from CTAD 2023?Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Subcutaneous PRX012 Aims for Better Efficacy and Superior Safety Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Key Takeaways from Prothena?s AD Pipeline Updates at AAIC Amsterdam
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX012-Neighbors? Envy, Owner?s Pride; Reit Buy and Raising PT to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX012?s Binding Profile Might Predict Efficacy - Takeaways from AD/PD 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
NfL Might be the Best Predictor of Motor Progression in PD-Takeaways from AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Tau368, An Alternative CSF Biomarker for AD Pathology-Takeaways from AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A